Johnson & Johnson has issued a downward revision to its earnings per share (EPS) guidance for fiscal years 2026 and 2027, citing expected decreases in both adjusted operational and adjusted metrics. The announcement, made via an SEC filing, signals a contraction in the company’s near-term profitability outlook as it adjusts expectations for future performance.

The specific adjustments reflect a significant reduction in projected earnings power over the next two years. For fiscal year 2026, Johnson & Johnson expects its adjusted operational EPS and adjusted EPS to decrease by $0.64. The outlook for fiscal year 2027 shows a further widening of this gap, with both adjusted operational EPS and adjusted EPS expected to decrease by $1.36.

Guidance Revisions

The following table outlines the specific downward adjustments to Johnson & Johnson’s EPS guidance as disclosed in the filing:

What the Numbers Show

The magnitude of the revision for 2027, which is more than double the reduction seen for 2026, suggests that Johnson & Johnson anticipates continued pressure on its earnings profile in the medium term. By lowering both operational and total adjusted EPS figures, the company is signaling that these headwinds are likely structural or persistent rather than isolated to a single quarter. Investors should monitor subsequent filings for details on whether these reductions stem from increased costs, lower revenue projections, or other strategic shifts.

Johnson & Johnson announced on July 27, 2026, that it has reached a comprehensive agreement to resolve approximately 76,000 ovarian cancer and mesothelioma claims linked to its talc products. The $5.5 billion settlement is contingent upon lead plaintiff firms representing at least 95% of remaining claims in federal Multi-District Litigation (MDL) and state court proceedings. This development marks a definitive shift from prolonged litigation to a structured resolution, aiming to eliminate the expense of defending individual cases while providing compensation through an uncapped, tiered grid system. The first payment of no more than $3 billion is scheduled for 2027, with no additional payments due before 2028.

Settlement Structure and Conditions

The proposed resolution requires significant buy-in from plaintiffs to proceed. Under the terms, Johnson & Johnson will make per-claim payments determined by objective criteria. The financial commitment is structured in phases: the initial payment is capped at $3 billion in 2027, with no additional payments due before 2028. Notably, the settlement fund is uncapped, meaning the total payout is not limited to a fixed pool but depends on the number of qualifying claims. The Plaintiffs' Executive Committee has unanimously supported the agreement, signaling broad acceptance among lead counsel.

Legal Context and Causation Rulings

The proposal emerges after a decade of legal battles, including three rejected Chapter 11 bankruptcy attempts between 2021 and 2025. In March 2025, a bankruptcy court rejected the company’s third plan, after which Johnson & Johnson chose not to appeal. Subsequent legal developments strengthened the company’s position; in January 2026, a Special Master ruled that plaintiffs could present expert testimony on general causation in ovarian cancer cases. However, in July 2026, the MDL court ordered plaintiffs to demonstrate why pending claims should not be dismissed after they withdrew specific causation experts in two bellwether cases. Erik Haas, Worldwide Vice President of Litigation at Johnson & Johnson, stated that these rulings confirmed the company’s view that the claims lack scientific merit.

Key Legal Milestones

What the Numbers Show

The settlement represents one of the largest products liability resolutions in U.S. history, resolving roughly 76,000 claims. By conditioning the deal on 95% participation, Johnson & Johnson mitigates the risk of holdout claimants seeking higher individual verdicts. The uncapped nature of the fund contrasts with previous bankruptcy proposals that sought to limit total exposure. With approximately 95% of filed mesothelioma lawsuits already settled, this agreement aims to close the remaining ovarian cancer chapter, allowing the company to focus on its core medicines and devices business.